The purpose of this study is to determine whether transcutaneous electrical nerve stimulation (TENS) delivered via the Empi Select TENS device provides relief of chronic lower back pain.
The E-STIM Trial is designed to collect data on the efficacy of the Empi Select Transcutaneous Electrical Nerve Stimulation (TENS) device for the treatment of chronic low back pain. This clinical trial is a non-significant risk, randomized, double-blinded, placebo-controlled 12-week trial involving the commercially available Empi Select TENS device for treating subjects with chronic (\>90 days) low back pain. Multiple centers located in the United States will enroll approximately 300 subjects in this study. Eligible subjects will be randomized 1:1 to either the treatment group or the placebo group. The subjects and investigational staff are blinded to the treatment assignment. Subjects will return to the investigational center for follow-up assessments at 1, 4, 8, and 12 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
300
The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
MedInvestigations
Fair Oaks, California, United States
RECRUITINGPain Consultants of West Florida
Pensacola, Florida, United States
RECRUITINGSuncoast Neuroscience Associates, Inc.
St. Petersburg, Florida, United States
Relief of lower back pain as measured by a Numerical Rating Scale (NRS) of Average Daily Pain.
Time frame: Baseline and at 1, 4, 8 and 12 week follow-up
Improvement of function as measured by the Roland and Morris Back Pain Disability Scale.
Time frame: Baseline and 1, 4, 8 and 12 week follow-up
Improvement of quality of life as measured by the SF-12 Health Survey.
Time frame: Baseline and 1, 4, 8 and 12 week follow-up
Subject satisfaction as measured by the Patient Global Impression of Change scale (PGIC).
Time frame: 1, 4, 8 and 12 week follow-up
Adverse Event Assessment: assess the occurrence and severity of any adverse events.
Time frame: 1, 4, 8 and 12 week follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Center for Prospective Outcome Studies
Atlanta, Georgia, United States
RECRUITINGTaylor Research LLC
Marietta, Georgia, United States
RECRUITINGMillennium Pain Center
Bloomington, Illinois, United States
RECRUITINGClinical Research Source, Inc.
Perrysburg, Ohio, United States
RECRUITINGSpinal Research Foundation
Reston, Virginia, United States
RECRUITING